HIV DRUG DOLUTEGRAVIR (DTG)

The World Health Organisation (WHO) has recommended the use of the HIV drug dolutegravir (DTG).

• It is safe for pregnant women and those of childbearing potential.
• Initial studies had highlighted a possible link between DTG and neural tube defects (birth defects of the brain and spinal cord) in infants born to women using the drug at the time of conception.
• New data comparing the efficacy and safety of DTG and efavirenz (EFV) have now expanded the evidence base and prove that the risks of neural tube defects are significantly lower than what the initial studies may have suggested.
• DTG is more effective, easier to take and has fewer side effects than alternative drugs.
• It also has a high genetic barrier to developing drug resistance, which is important, given the rising trend of resistance.
• The new recommendations aim at helping more nations improve their HIV policies.

Source: The Hindu

Also, read more daily News

• Rising Temperature caused by “Omega Block”
• Addressing the challenge of Red Mud
• International Tiger Day – 29 July 2019
• GST rate cut on Electric Vehicle 
• Report on Great Indian Bustard
• Deep Ocean Mission
• People’s Choice Award 

You are on the Best Online IAS coaching platform. You are learning under experts.

We are present on Facebook- Diligent IAS, LinkedIn- Diligent IAS, YouTube- Diligent IAS, Instagram- Diligent IAS. Get in touch with us.